Shots:
- In the HIBISCUS I induction study, in patients without prior anti-TNF treatment, etrolizumab met its 1EPs while in HIBISCUS II study in the same kind of people, it did not meet its 1EPs. In the HICKORY study, in patients with prior anti-TNF treatment, therapy met its 1EPs at induction but not at maintenance
- In the LAUREL maintenance study in people without prior anti-TNF treatment, etrolizumab failed to meet its 1EPs while the safety profile of therapy was consistent with previous studies and no major safety issues were reported till date in the four P-III studies
- The therapy is currently being evaluated as an induction/maintenance treatment in people with mod. to sev. active CD with/out prior anti-TNF treatment in a global P-III study (BERGAMOT) and OLE and safety monitoring study (JUNIPER), involving 1,100+ people with CD. In addition, Roche is studying other therapies in IBD and is committed to further understanding this disease
Click here to read full press release/ article | Ref: Roche | Image: Pantone Canvas Gallery
